Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

174
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
174
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

248
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
248
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

227
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
227
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

126
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
126
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

259
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
259

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A proteome-wide atlas of humoral immunity to <i>Mycobacterium tuberculosis</i> across the spectrum of disease.

Frontiers in immunology·2026
Same author

Deep learning approach for probabilistic pulmonary function estimation from chest X-ray and peak expiratory flow rate.

Communications medicine·2026
Same author

Successful neonatal outcome after postmortem caesarean section at Sumbawanga Regional Referral Hospital, Rukwa, Tanzania: case report.

BMC pregnancy and childbirth·2026
Same author

Safety of short-course weekly rifapentine and isoniazid (3HP) for TB preventive treatment at conception and during first trimester in women living with HIV: a secondary analysis of WHIP3TB trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Design and feasibility considerations for a phase 3 efficacy trial of the M72/AS01<sub>E-4</sub> tuberculosis vaccine.

Vaccine·2026
Same author

Expanding Xpert MTB/RIF Ultra and lateral flow urine lipoarabinomannan testing for diagnosis of tuberculosis among adults living with HIV admitted to hospitals in Tanzania and Mozambique (EXULTANT): a randomised controlled trial.

The Lancet. Infectious diseases·2026

Related Experiment Video

Updated: Jun 15, 2025

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

18.9K

Adjunctive N-Acetylcysteine and Lung Function in Pulmonary Tuberculosis.

Robert S Wallis1,2,3, Issa Sabi4, Julieth Lalashowi4

  • 1The Aurum Institute, Johannesburg.

NEJM Evidence
|August 27, 2024
PubMed
Summary

N-acetylcysteine (NAC) did not improve tuberculosis eradication but enhanced lung function recovery in patients with moderate to far-advanced pulmonary tuberculosis. Further research is recommended for its potential benefits on lung health.

More Related Videos

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD &#8212; A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

731
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

33.0K

Related Experiment Videos

Last Updated: Jun 15, 2025

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection
10:10

A 3D Human Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection

Published on: October 5, 2015

18.9K
Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD &#8212; A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

731
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

33.0K

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Clinical Pharmacology

Background:

  • Tuberculosis (TB) is a major global health issue, often leading to permanent lung damage in survivors.
  • N-acetylcysteine (NAC) exhibits antimicrobial, antioxidant, and immunomodulatory properties beneficial in preclinical TB models.

Purpose of the Study:

  • To evaluate the efficacy of N-acetylcysteine (NAC) as an adjunct therapy for tuberculosis treatment outcomes.
  • To assess the impact of NAC on Mycobacterium tuberculosis (MTB) eradication and lung function in patients with moderate to far-advanced TB.

Main Methods:

  • A prospective, randomized, controlled trial involving 140 adults with moderate to far-advanced TB.
  • Participants received standard therapy with or without 1200 mg oral NAC twice daily for 112 days.
  • Primary outcome was sputum culture conversion; secondary outcomes included glutathione levels and lung function (spirometry).

Main Results:

  • NAC significantly increased whole-blood glutathione levels but did not improve culture conversion rates for Mycobacterium tuberculosis.
  • NAC treatment was associated with improved lung function recovery, particularly in participants with severe baseline impairment.
  • Adverse event rates were similar between the NAC and placebo groups.

Conclusions:

  • While NAC boosts glutathione, it does not enhance MTB eradication in pulmonary tuberculosis.
  • NAC shows promise for improving lung function recovery in TB patients, warranting further investigation.
  • The study was funded by the German Ministry for Education and Research and registered under NCT03702738.